Aspire Biopharma (ASBP) announced that the Company’s Board of Directors has appointed Kraig Higginson as interim Chief Executive Officer, effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for four years. Michael C. Howe has resigned as CEO and as a member of the Board. The Board thanks Mr. Howe for his contributions to the Company and plans to initiate a search for a permanent CEO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire Biopharma Announces Leadership Reshuffle Amid Resignations
- Aspire Biopharma announces ‘positive’ consumer feedback on Buzz Bomb
- Aspire announces last patient dosed in Phase 1 trial of aspirin formulation
- Aspire Biopharma Relocates Executive Office to Florida
- Aspire Biopharma Appoints New CEO Michael C. Howe